Health Topics: Page 2

Target ALS launches new data portal for research

By Matt Limb

A nonprofit medical research foundation has launched a data portal designed to help spur scientific breakthroughs for the disease amyotrophic lateral sclerosis (ALS).

April 23, 2024

Roche, Lilly Alzheimer's blood test granted FDA breakthrough device designation

By LabPulse.com staff writers

The Alzheimer's blood test developed through a collaboration between Roche and Lilly has been granted a breakthrough device designation by the U.S. Food and Drug Administration (FDA).

April 11, 2024

Skin biopsy test shows promise for detection of neurogenerative diseases

By Matt Limb

A simple skin biopsy test has shown a high accuracy rate in detecting an abnormal form of alpha-synuclein, the pathological hallmark of Parkinson's disease and other synucleinopathies, say neurologists.

April 5, 2024

U.K. team develops new approach to detect signs of motor neuron disease

By Matt Limb

Scientists have identified a new way to detect signs of motor neuron disease (MND) in brain tissue, raising hopes for early diagnosis and intervention before onset of symptoms.

April 3, 2024

Bluebird Bio secures up to $175M in debt financing

By LabPulse.com staff writers

Bluebird Bio has secured up to $175 million in debt financing with Hercules Capital, having entered into a five-year term loan facility that provides funds in separate tranches.

March 18, 2024

FDA updates draft guidance for Alzheimer's drug development biomarkers

By LabPulse.com staff writers

The U.S. Food and Drug Administration (FDA) has released an updated draft guidance for the use of biomarkers aimed at sponsors and pharmaceutical companies developing drugs intended to treat early Alzheimer's disease.

March 14, 2024

Bluebird Bio signs state Medicaid agreement for SCD gene therapy

By LabPulse.com staff writers

Bluebird Bio has signed its first outcomes-based Medicaid agreement for its sickle-cell disease (SCD) gene therapy Lyfgenia with the state of Michigan.

March 11, 2024

Eisai invests $15M in C2N to increase Alzheimer's test access

By LabPulse.com staff writers

C2N Diagnostics has announced that pharmaceutical company Eisai has agreed to invest up to $15 million in C2N to provide broader access to Alzheimer’s disease tests.

March 6, 2024

Alzheimer’s study results show correlation between blood-based biomarkers and amyloid plaques

By LabPulse.com staff writers

The first results from the Bio-Hermes study have been released, showing a strong correlation between several blood-based and digital biomarkers with the presence of amyloid plaques in the brain, a diagnostic hallmark of Alzheimer's disease (AD).

March 1, 2024

Study: Novel type of inhibitor may prevent microvascular diabetic complications

By Matt Limb

A new type of inhibitor drug could prevent microvascular diabetic complications, such as diabetic eye and kidney disease, research suggests.

February 15, 2024

NHS lacks capacity for Alzheimer’s diagnostics, warn experts

By Matt Limb

Many thousands of patients in the U.K. could miss out on new treatments for Alzheimer’s disease because its National Health Service (NHS) lacks capacity for diagnostic tests, warn experts.

February 14, 2024

Quest Diagnostics seeks to get a jump on PFAS testing in communities

By Liz Carey

Researchers often use people’s blood PFAS levels as a proxy for exposure to perfluoroalkyl and polyfluoroalkyl substances, the "forever chemicals" found in certain products and the environment.

February 13, 2024

Previous Page

Page 2 of 70

Next Page